Concepedia

Michael K. James

MK

25

Publications

1.3K

Citations

20

H-Index

1983

Active since

Affiliations

Research Triangle Park Foundation(Current)

Michigan State University

Inspire Institute

GlaxoSmithKline (Netherlands)

University of Illinois Chicago

Michael K. James is an author at Research Triangle Park Foundation specializing in medicine, pharmacology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

1983–2019

25

Publications

25

Unique Preclinical Characteristics of GG745, A Potent Dual Inhibitor of 5AR

H. Neal Bramson, David Hermann, Kenneth W. Batchelor et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 150 citations

Comparative Pharmacokinetics and Pharmacodynamics of Remifentanil, Its Principle Metabolite (GR90291) and Alfentanil in Dogs

John F. Hoke, Francesca Cunningham, Michael K. James et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 127 citations

Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues.

Michael K. James, Paul L. Feldman, Sascha Schuster et al. · Journal of Pharmacology and Experimental Therapeutics · 1991 · 119 citations

Effects of Remifentanil, a New Short-acting Opioid, on Cerebral Blood Flow, Brain Electrical Activity, and Intracranial Pressure in Dogs Anesthetized with Isoflurane and Nitrous Oxide

William E. Hoffman, Francesca Cunningham, Michael K. James et al. · Anesthesiology · 1993 · 101 citations · Full text

Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist “Trigger”

Christopher Aquino, Duncan Armour, Judd Berman et al. · Journal of Medicinal Chemistry · 1996 · 101 citations · Full text

, , +15

Rows per page

1–5 of 25